Acute Effects of Ibrutinib on Ventricular Arrhythmia in Spontaneously Hypertensive Rats-Reference-Cited by-同舟云学术

Acute Effects of Ibrutinib on Ventricular Arrhythmia in Spontaneously Hypertensive Rats

Published:2020-11 Issue:4 Volume:2 Page:614-629
ISSN:2666-0873
Container-title:JACC: CardioOncology
language:en
Short-container-title:JACC: CardioOncology

Author:

Du Beibei,Chakraborty Praloy,Azam Mohammed Ali,Massé Stéphane,Lai Patrick F.H.,Niri Ahmed,Si Daoyuan,Thavendiranathan Paaladinesh,Abdel-Qadir Husam,Billia Filio,Nanthakumar Kumaraswamy

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Oncology

Reference42 articles.

1. Current status of Bruton's tyrosine kinase inhibitor development and use in B-cell malignancies;Aw;Drugs Aging,2017

2. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia;Burger;N Engl J Med,2015

3. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results;Wang;Blood,2015

4. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib;Wiczer;Blood Adv,2017

5. Ibrutinib, an approved tyrosine kinase inhibitor as a potential cause of recurrent polymorphic ventricular tachycardia;Tomcsanyi;J Am Coll Cardiol EP,2016

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond;Frontiers in Pharmacology;2024-08-15

2. Impaired Cardiac AMPK (5′‐Adenosine Monophosphate‐Activated Protein Kinase) and Ca ²⁺ ‐Handling, and Action Potential Duration Heterogeneity in Ibrutinib‐Induced Ventricular Arrhythmia Vulnerability;Journal of the American Heart Association;2024-06-18

3. Arrhythmogenic Ventricular Remodeling by Next-Generation Bruton’s Tyrosine Kinase Inhibitor Acalabrutinib;International Journal of Molecular Sciences;2024-06-05

4. Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents;Cancers;2024-05-24

5. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database;Scientific Reports;2024-04-25